Skip to content

Failure of three main classes of antiretrovirals present in 12% of EuroSIDA cohort

Detectable viral load risk factor for new illness in those who start HAART with CD4 below 50

ICAAC: Tolerability key to superior showing of tenofovir/FTC in head to head match with Combivir

US HIV treatment guidelines revised

ICAAC: Combination of tenofovir and Trizivir as effective and tolerable as Combivir / efavirenz

Nevirapine effect on 'good' cholesterol outranks efavirenz or statins, 2NN study reports

French study finds older patients are diagnosed later and have slower immune reconstitution

Immune reconstitution inflammatory syndrome (IRIS) in the developing world

Initial NNRTI-based HAART regimens are sustained longer than PI-based HAART, Canadian study shows